Table of Contents
Hepatitis Research and Treatment
Volume 2010, Article ID 537827, 5 pages
http://dx.doi.org/10.1155/2010/537827
Clinical Study

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon

1Division of Digestive Diseases, Beth Israel Medical Center and Albert Einstein, College of Medicine, New York, NY 10003, USA
2Division of Gastroenterology, New York University Medical Center, New York, NY 10016, USA
3Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
4Division of Gastroenterology, Hepatology and Nutrition, North Shore University Hospital, Manhasset, NY 11030, USA

Received 17 April 2010; Revised 21 July 2010; Accepted 4 August 2010

Academic Editor: Tatehiro Kagawa

Copyright © 2010 Douglas F. Meyer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined. Methods. We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients. Results. Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance. Conclusions. The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance.